Background The FIREHAWK is a drug-eluting stent with a fully biodegradable sirolimus-
containing polymer coating localised to recessed abluminal grooves on the stent surface …

Objectives: This registry evaluated the safety and clinical outcomes of the Combo stent in an
all-comers population in routine clinical practice. We report 1-year results. Background …

Background The COMBO stent is a novel sirolimus-eluting stent with a luminal anti-CD34+
antibody layer to promote vessel healing. No data is currently available on clinical outcomes …

Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk
stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove …

Methods The study design, study population and endpoint definitions have been reported in
detail previously 3, 4. All major adverse events were adjudicated by an independent clinical …

Background Patients presenting with acute coronary syndrome (ACS) are at increased risk
of complications after percutaneous coronary intervention with stent placement compared to …

Objective The dual-therapy stent combines an abluminal biodegradable drug-eluting
coating, with a 'pro-healing'luminal layer. This bioengineered layer attracts circulating …

Background The bio‐engineered COMBO stent (OrbusNeich Medical BV, The Netherlands)
is a dual‐therapy pro‐healing stent. This novel technology may allow a shorter duration of …

Objectives This final report from the REMEDEE Registry assessed the long‐term safety and
efficacy of the dual‐therapy COMBO stent in a large unselected patient population …

Background Data of long-term safety and efficacy of the COMBO dual-therapy stent is
lacking. REMEDEE Registry evaluated the COMBO stent and showed low clinical event …